Stereotactic ablative radiation therapy for centrally located early stage or isolated parenchymal recurrences of non-small cell lung cancer: how to fly in a "no fly zone"
- PMID: 24661665
- DOI: 10.1016/j.ijrobp.2014.01.022
Stereotactic ablative radiation therapy for centrally located early stage or isolated parenchymal recurrences of non-small cell lung cancer: how to fly in a "no fly zone"
Abstract
Purpose: We extended our previous experience with stereotactic ablative radiation therapy (SABR; 50 Gy in 4 fractions) for centrally located non-small cell lung cancer (NSCLC); explored the use of 70 Gy in 10 fractions for cases in which dose-volume constraints could not be met with the previous regimen; and suggested modified dose-volume constraints.
Methods and materials: Four-dimensional computed tomography (4DCT)-based volumetric image-guided SABR was used for 100 patients with biopsy-proven, central T1-T2N0M0 (n=81) or isolated parenchymal recurrence of NSCLC (n=19). All disease was staged with positron emission tomography/CT; all tumors were within 2 cm of the bronchial tree, trachea, major vessels, esophagus, heart, pericardium, brachial plexus, or vertebral body. Endpoints were toxicity, overall survival (OS), local and regional control, and distant metastasis.
Results: At a median follow-up time of 30.6 months, median OS time was 55.6 months, and the 3-year OS rate was 70.5%. Three-year cumulative actuarial local, regional, and distant control rates were 96.5%, 87.9%, and 77.2%, respectively. The most common toxicities were chest-wall pain (18% grade 1, 13% grade 2) and radiation pneumonitis (11% grade 2 and 1% grade 3). No patient experienced grade 4 or 5 toxicity. Among the 82 patients receiving 50 Gy in 4 fractions, multivariate analyses showed mean total lung dose >6 Gy, V20 >12%, or ipsilateral lung V30 >15% to independently predict radiation pneumonitis; and 3 of 9 patients with brachial plexus Dmax >35 Gy experienced brachial neuropathy versus none of 73 patients with brachial Dmax <35 Gy (P=.001). Other toxicities were analyzed and new dose-volume constraints are proposed.
Conclusions: SABR for centrally located lesions produces clinical outcomes similar to those for peripheral lesions when normal tissue constraints are respected.
Copyright © 2014 Elsevier Inc. All rights reserved.
Comment in
-
Stereotactic ablative radiation therapy for centrally located recurrences of non-small cell lung cancer: in regard to Chang et al.Int J Radiat Oncol Biol Phys. 2014 Aug 1;89(5):1141-1142. doi: 10.1016/j.ijrobp.2014.04.037. Epub 2014 Jul 8. Int J Radiat Oncol Biol Phys. 2014. PMID: 25035222 No abstract available.
-
In reply to Oskan.Int J Radiat Oncol Biol Phys. 2014 Aug 1;89(5):1142. doi: 10.1016/j.ijrobp.2014.04.034. Epub 2014 Jul 8. Int J Radiat Oncol Biol Phys. 2014. PMID: 25035223 No abstract available.
Similar articles
-
Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non-small-cell lung cancer.Int J Radiat Oncol Biol Phys. 2008 Nov 15;72(4):967-71. doi: 10.1016/j.ijrobp.2008.08.001. Int J Radiat Oncol Biol Phys. 2008. PMID: 18954709 Free PMC article. Clinical Trial.
-
Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage I non-small cell lung cancer.Radiat Oncol. 2012 Sep 10;7:152. doi: 10.1186/1748-717X-7-152. Radiat Oncol. 2012. PMID: 22963661 Free PMC article. Clinical Trial.
-
Stereotactic ablative radiotherapy (SABR) using 70 Gy in 10 fractions for non-small cell lung cancer: exploration of clinical indications.Radiother Oncol. 2014 Aug;112(2):256-61. doi: 10.1016/j.radonc.2014.07.010. Epub 2014 Aug 6. Radiother Oncol. 2014. PMID: 25108807
-
Stereotactic ablative radiotherapy for centrally located early stage non-small-cell lung cancer: what we have learned.J Thorac Oncol. 2015 Apr;10(4):577-85. doi: 10.1097/JTO.0000000000000453. J Thorac Oncol. 2015. PMID: 25514807 Review.
-
Local Control After Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer.Int J Radiat Oncol Biol Phys. 2021 May 1;110(1):160-171. doi: 10.1016/j.ijrobp.2019.03.045. Epub 2019 Apr 5. Int J Radiat Oncol Biol Phys. 2021. PMID: 30954520 Free PMC article. Review.
Cited by
-
Stereotactic body radiotherapy in lung cancer: a contemporary review.Pathol Oncol Res. 2024 Feb 27;30:1611709. doi: 10.3389/pore.2024.1611709. eCollection 2024. Pathol Oncol Res. 2024. PMID: 38476352 Free PMC article. Review.
-
Long-Term Outcomes of Ablative Carbon-Ion Radiotherapy for Central Non-Small Cell Lung Cancer: A Single-Center, Retrospective Study.Cancers (Basel). 2024 Feb 25;16(5):933. doi: 10.3390/cancers16050933. Cancers (Basel). 2024. PMID: 38473295 Free PMC article.
-
CyberKnife® stereotactic radiation therapy for stage I lung cancer and pulmonary oligometastases: is fiducial implantation still relevant?-a cohort study.J Thorac Dis. 2023 Sep 28;15(9):4636-4647. doi: 10.21037/jtd-22-1245. Epub 2023 Aug 11. J Thorac Dis. 2023. PMID: 37868838 Free PMC article.
-
Development of a multi-feature-combined model: proof-of-concept with application to local failure prediction of post-SBRT or surgery early-stage NSCLC patients.Front Oncol. 2023 Sep 13;13:1185771. doi: 10.3389/fonc.2023.1185771. eCollection 2023. Front Oncol. 2023. PMID: 37781201 Free PMC article.
-
An optimal dose-fractionation for stereotactic body radiotherapy in peripherally, centrally and ultracentrally located early-stage non-small lung cancer.Thorac Cancer. 2023 Oct;14(28):2813-2820. doi: 10.1111/1759-7714.15071. Epub 2023 Sep 10. Thorac Cancer. 2023. PMID: 37691151 Free PMC article. Review.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
